Hillenmayer Anna, Wertheimer Christian M, Hillenmayer Marlene, Strehle Laura D, Hartmann Lennart M, Vounotrypidis Efstathios, Wolf Armin
Department of Ophthalmology, University of Ulm, Prittwitzstr. 43, 89075, Ulm, Germany.
BMC Ophthalmol. 2024 Dec 9;24(1):525. doi: 10.1186/s12886-024-03794-y.
BACKGROUND/AIMS: Submacular haemorrhages (SMH) cause significant visual impairment. Until now, the comparative effectiveness of different treatment approaches remains inconclusive without clear treatment guidelines. The aim of our study was to evaluate the effectiveness of 5 surgical treatment modalities in terms of visual prognosis and success rate.
This retrospective study included 201 patients with SMH. Primary endpoint was best corrected visual acuity (BCVA), secondary endpoints included haemorrhage size and complications. Group 1 was treated with pneumatic displacement and rtPA-injection. Group 2 followed the "Manchester protocol" with rtPA-injection and-if needed-a standardised secondary procedure with pars plana vitrectomy (ppV) and subretinal rtPA. Group 3 underwent vitrectomy with subretinal rtPA, group 4 vitrectomy only and group 5 received subretinal lavage.
Baseline characteristics were a mean age of 79 years and a follow-up of 4.6 months. Pre-intervention BCVA of 1.7 logMAR improved to 1.4 logMAR at follow-up. A gain of > 0.2 logMAR was achieved in 47% of patients, while 20% lost > 0.2 logMAR. Only group 2 achieved a statistically significant visual gain. While group 5 was statistically larger in haemorrhage size preoperatively (p < 0.05), all groups were statistically equal in SMH size at follow-up. Complications led to additional interventions in 20% of patients.
No significant change in visual prognosis could be achieved depending on the intervention. As more invasive techniques seem to lack the benefit of a better postoperative prognosis while carrying higher risks, it may be beneficial considering a less invasive option first.
背景/目的:黄斑下出血(SMH)会导致严重的视力损害。到目前为止,不同治疗方法的相对有效性仍无定论,也没有明确的治疗指南。我们研究的目的是评估5种手术治疗方式在视力预后和成功率方面的有效性。
这项回顾性研究纳入了201例SMH患者。主要终点是最佳矫正视力(BCVA),次要终点包括出血大小和并发症。第1组采用气体置换和rtPA注射治疗。第2组遵循“曼彻斯特方案”,进行rtPA注射,必要时采用标准化的二次手术,即经平坦部玻璃体切除术(ppV)和视网膜下rtPA。第3组接受玻璃体切除术联合视网膜下rtPA,第4组仅接受玻璃体切除术,第5组接受视网膜下冲洗。
基线特征为平均年龄79岁,随访4.6个月。干预前BCVA为1.7 logMAR,随访时改善至1.4 logMAR。47%的患者视力提高>0.2 logMAR,而20%的患者视力下降>0.2 logMAR。只有第2组在视力改善方面具有统计学意义。虽然第5组术前出血大小在统计学上更大(p<0.05),但所有组在随访时SMH大小在统计学上相等。并发症导致20%的患者需要额外干预。
根据干预方式的不同,视力预后没有显著变化。由于侵入性更强的技术似乎缺乏更好的术后预后优势,同时风险更高,因此首先考虑侵入性较小的选择可能是有益的。